Home › High Blood Pressure in Pregnancy › NCT05309460
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
RecruitingPhase 4
Who can join
Ages 19 and older · Women
Full eligibility criteria
Inclusion Criteria: Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension. Exclusion Criteria: History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema * Contraindication to either Nifedipine or Labetalol * HR \<60 or \>110 * Native language other than English or Spanish
About the study
Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.
What is being tested
- Labetalol Oral Tablet (drug)
- NIFEdipine ER (drug)
Sponsor: Nebraska Methodist Health System · Participants: 600 · Started: Jun 20, 2022
Contact the study team
- Todd Lovgren, MD · Phone: 4028151970
- Joshua Dahlke, MD · Phone: 4028151970
Official record on ClinicalTrials.gov — NCT05309460
Locations in the U.S.
| Nebraska | Nebraska Methodist Women's Hospital, Omaha |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.